116 results found.

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Case Comprehensive Cancer Center - Recruiting 18 years to 70 years.
- A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML).
bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Leukemia, Myeloid, Acute Clinical Trial using Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia.
Volasertib

Leukemia, Myeloid, Acute Clinical Trial using placebo; volasertib; low dose cytarabine

Boehringer Ingelheim - Recruiting N/A or older.
- A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy.
placebo; volasertib; low dose cytarabine

Leukemia, Myeloid, Acute Clinical Trial using decitabine iv; volasertib iv infusion

Boehringer Ingelheim - Recruiting 60 years or older.
- An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia.
decitabine iv; volasertib iv infusion

Leukemia, Myeloid, Acute Clinical Trial using BI 836858

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia..
BI 836858

Disorder Related to Bone Marrow Transplantation, Leukemia, or Tra Clinical Trial using Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 3 years to 70 years.
- A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Leukemia, Myeloid, Acute Clinical Trial using 300 mg Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 55 years or older.
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission.
300 mg Oral Azacitidine; Placebo

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodys Clinical Trial using Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 44 years.
- Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies.
Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Leukemia Clinical Trial using sargramostim; busulfan; cyclophosphamide; dexamethasone; etoposide; bone marrow transplantation; hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 70 years.
- Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL).
sargramostim; busulfan; cyclophosphamide; dexamethasone; etoposide; bone marrow transplantation; hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Acute Myeloid Leukemia Clinical Trial using IPH2102 at 0.1 mg/kg; IPH2102 at 1 mg/kg; Placebo (normal saline solution)

Innate Pharma - Recruiting 60 years to 80 years.
- Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission.
IPH2102 at 0.1 mg/kg; IPH2102 at 1 mg/kg; Placebo (normal saline solution)

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblast Clinical Trial using Sirolimus; Idarubicin; Cytarabine

Thomas Jefferson University - Recruiting 18 years or older.
- A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia.
Sirolimus; Idarubicin; Cytarabine

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 2 years or older.
- A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML.
clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Leukemia Clinical Trial using Vosaroxin; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome.
Vosaroxin; Decitabine

Leukemia Clinical Trial using Cladribine; Cytarabine; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Cladribine; Cytarabine; Decitabine

Acute Myelogenous Leukemia, AML, or Acute Myeloid Leukemia Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML).
ABT-199

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using cytarabine; lenalidomide

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients.
cytarabine; lenalidomide

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial using Treosulfan

Center for International Blood and Marrow Transplant Research - Recruiting N/A to 21 years.
- A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation.
Treosulfan

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 80 years.
- Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study.

Acute Myeloid Leukemia Clinical Trial using DAC; CLAG; Consolidation, I HAM cycle; II Consolidation HiDAraC; Consolidation, III HiDAraC cycle

Polish Adult Leukemia Group - Recruiting 18 years to 60 years.
- Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells.
DAC; CLAG; Consolidation, I HAM cycle; II Consolidation HiDAraC; Consolidation, III HiDAraC cycle

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 74 years.
- Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML).
pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Acute Myeloid Leukemia Clinical Trial using Phase1 and Phase 2: decitabine; Phase 1: cytarabine; Phase 2: cytarabine

Janssen Research & Development, LLC - Recruiting 1 Month to 18 years.
- Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia.
Phase1 and Phase 2: decitabine; Phase 1: cytarabine; Phase 2: cytarabine

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation.
fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using standard follow-up care; medical chart review; quality-of-life assessment

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 75 years.
- Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML.
standard follow-up care; medical chart review; quality-of-life assessment

Acute Myeloid Leukemia (AML), or Acute Lymphocytic Leukemia (ALL) Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia.
CB-839

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, or Leuk Clinical Trial using Allogeneic Lymphocytes; Fludarabine; Cyclophosphamide; Methylprednisolone; Cyclosporine

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 75 years.
- Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation.
Allogeneic Lymphocytes; Fludarabine; Cyclophosphamide; Methylprednisolone; Cyclosporine

Acute Myeloid Leukemia Clinical Trial using pracinostat with azacitadine

MEI Pharma, Inc. - Recruiting 65 years or older.
- A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
pracinostat with azacitadine

Leukemia Clinical Trial using Cytarabine; Lintuzumab-Ac225; Lasix; Spironolactone

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia.
Cytarabine; Lintuzumab-Ac225; Lasix; Spironolactone

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate.
pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Leukemia Clinical Trial using Quizartinib; Cytarabine; AZA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase I/Phase II.
Quizartinib; Cytarabine; AZA

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis.
laboratory biomarker analysis

Leukemia, Myeloid, Acute Clinical Trial using Lenalidomide; Azacitidine

Washington University School of Medicine - Recruiting 18 years or older.
- Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia.
Lenalidomide; Azacitidine

Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adu Clinical Trial using atorvastatin calcium; fludarabine phosphate; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation.
atorvastatin calcium; fludarabine phosphate; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; laboratory biomarker analysis

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using WT1 peptide vaccine

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL).
WT1 peptide vaccine

Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Ac Clinical Trial using supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Children's Oncology Group - Recruiting 4 years to 21 years.
- A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.
supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 6 Months to 45 years.
- Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies.
ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Acute Myeloid Leukemia Clinical Trial using PF-04449913; Low dose ARA-C (LDAC); Decitabine; Daunorubicin; Cytarabine; Pf-04449913

Pfizer - Recruiting 18 years or older.
- A Phase 1B/2 Study To Evaluate The Safety And Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome.
PF-04449913; Low dose ARA-C (LDAC); Decitabine; Daunorubicin; Cytarabine; Pf-04449913

Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; cyclosporine; methotrexate; methylprednisolone; tacrolimus; laboratory biomarker analysis; pharmacological study; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation

Children's Oncology Group - Recruiting N/A to 30 years.
- Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study.
anti-thymocyte globulin; busulfan; cyclophosphamide; cyclosporine; methotrexate; methylprednisolone; tacrolimus; laboratory biomarker analysis; pharmacological study; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML).
cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myel Clinical Trial using Hedgehog inhibitor PF-04449913

University of Colorado, Denver - Recruiting 18 years or older.
- A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse.
Hedgehog inhibitor PF-04449913

Acute Myeloid Leukemia Clinical Trial using Sapacitabine and decitabine; Decitabine

Cyclacel Pharmaceuticals, Inc. - Recruiting 70 years or older.
- A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Sapacitabine and decitabine; Decitabine

High Risk Acute Myeloid Leukemia Clinical Trial using CPX-351; 7+3 (cytarabine and daunorubicin)

Celator Pharmaceuticals - Recruiting 60 years to 75 years.
- Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML.
CPX-351; 7+3 (cytarabine and daunorubicin)

Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Le Clinical Trial using sorafenib tosylate; bone marrow transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance.
sorafenib tosylate; bone marrow transplantation; laboratory biomarker analysis

Acute Myeloid Leukemia Clinical Trial using PGX-ODSH-2013-AML-1

Cantex Pharmaceticals - Recruiting 18 years to 80 years.
- A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia.
PGX-ODSH-2013-AML-1

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Children's Oncology Group - Recruiting N/A or older.
- Umbrella Long-Term Follow-Up Protocol.
survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 16 years to 50 years.
- A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome.
iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Acute Myeloid Leukemia Clinical Trial using AZD1208

AstraZeneca - Recruiting 18 years or older.
- A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).
AZD1208

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using caspofungin acetate; fluconazole; laboratory biomarker analysis

Children's Oncology Group - Recruiting 3 Months to 30 years.
- A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML).
caspofungin acetate; fluconazole; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study.
decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chr Clinical Trial using Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

M.D. Anderson Cancer Center - Recruiting 5 years to 75 years.
- Randomized Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation.
Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

Acute Myeloid Leukemia Clinical Trial using Multiplex respiratory viral PCR

Centre Hospitalier Universitaire, Amiens - Recruiting 18 years to 85 years.
- Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy.
Multiplex respiratory viral PCR

Acute Myeloid Leukemia Clinical Trial using GRASPA

ERYtech Pharma - Recruiting 65 years to 85 years.
- A Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients, Over 65 Years, Unfit for Intensive Chemotherapy..
GRASPA

Pediatric Acute Myeloblastic Leukemia Clinical Trial using Randomisation course 1 mitoxantrone versus DaunoXome; Randomisation course 2 ADxE versus FLADx

Vastra Gotaland Region - Recruiting N/A to 18 years.
- NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years.
Randomisation course 1 mitoxantrone versus DaunoXome; Randomisation course 2 ADxE versus FLADx

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodyspla Clinical Trial using EPZ-5676

Epizyme, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies.
EPZ-5676

Acute Myeloid Leukemia Clinical Trial using Midostaurin (PKC412); Standard of Care

Novartis - Recruiting 18 years to 60 years.
- A Phase II, Randomized, Comparative Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia.
Midostaurin (PKC412); Standard of Care

AML Subjects Who Have Failed Prior Systemic Therapy Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 18 years or older.
- Phase 2 Study of ADI-PEG 20 in Relapsed/Refractory Acute Myeloid Leukemia.
ADI-PEG 20

Leukemia Clinical Trial using Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML).
Decitabine

Thrombocytopaenia Clinical Trial using eltrombopag; placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension).
eltrombopag; placebo

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasi Clinical Trial using Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

St. Jude Children's Research Hospital - Recruiting N/A to 24 Months.
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies.
Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML).
daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using lenalidomide; laboratory biomarker analysis

Albert Einstein College of Medicine of Yeshiva University - Recruiting 60 years to 75 years.
- A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML).
lenalidomide; laboratory biomarker analysis

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myel Clinical Trial using clofarabine; melphalan; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 75 years.
- Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission.
clofarabine; melphalan; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Chronic Myeloid Leukemia or Ph Positive ALL Clinical Trial

Seoul St. Mary's Hospital - Recruiting 18 years or older.
- Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA): A Retrospective Feasibility Study.

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Acute Myeloid Leukemia, or Chronic Lymphocytic Leukemia Clinical Trial using SG2000

Spirogen - Recruiting 18 years to 60 years.
- An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.
SG2000

Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), My Clinical Trial using Sorafenib; Cytarabine; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 31 years.
- A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Sorafenib; Cytarabine; Clofarabine

Leukemia Clinical Trial using E7070; Idarubicin; Cytarabine; Dexamethasone

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes.
E7070; Idarubicin; Cytarabine; Dexamethasone

Acute Myeloid Leukemia, or Myelodysplastic Syndromes Clinical Trial using CD8+ T-cell depleted donor lymphocyte infusion

National University Hospital, Singapore - Recruiting 21 years to 90 years.
- Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS).
CD8+ T-cell depleted donor lymphocyte infusion

Leukemia, Myeloid Clinical Trial using autologous hematopoietic cell transplantation

Asan Medical Center - Recruiting 15 years to 65 years.
- Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission.
autologous hematopoietic cell transplantation

Myelodysplastic Syndrome, or Acute Myeloid Leukemia Clinical Trial using BX2; BX3; BX4

Institut Paoli-Calmettes - Recruiting 18 years to 65 years.
- Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies.
BX2; BX3; BX4

Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Clinical Trial using asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 29 years.
- A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD.
asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using decitabine

Washington University School of Medicine - Recruiting 18 years or older.
- Genomic Predictors of Decitabine Response in AML/MDS.
decitabine

Acute Myeloid Leukemia Clinical Trial using Liposomal amphotericin B

Bayside Health - Recruiting 18 years to 80 years.
- A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisomer in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia.
Liposomal amphotericin B

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias.
temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chr Clinical Trial using total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 21 years.
- A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children.
total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia Clinical Trial using US-ATG-F; Placebo

Neovii Biotech - Recruiting 18 years to 65 years.
- Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors.
US-ATG-F; Placebo

Acute Myeloid Leukemia Clinical Trial using Cytarabine; Daunorubicin; Etoposide; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia.
Cytarabine; Daunorubicin; Etoposide; Clofarabine

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using pentostatin; therapeutic allogeneic lymphocytes; mycophenolate mofetil; cyclosporine

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multi-Center Trial.
pentostatin; therapeutic allogeneic lymphocytes; mycophenolate mofetil; cyclosporine

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML.
WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using chemotherapy

University of Washington - Recruiting 18 years to 59 years.
- Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome.
chemotherapy

Acute Lymphocytic Leukemia, or Acute Myeloid Leukemia Clinical Trial

St. Jude Children's Research Hospital - Recruiting 5 years or older.
- Transfusional Iron Overload Among Leukemia Survivors.

Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodys Clinical Trial using Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Masonic Cancer Center, University of Minnesota - Recruiting 1 year to 70 years.
- Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant.
Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), A Clinical Trial using NiCordr

Gamida Cell ltd - Recruiting 18 years to 65 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adult Patients With Hematological Malignancies.
NiCordr

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblast Clinical Trial using azacitidine; cytarabine; mitoxantrone hydrochloride; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML).
azacitidine; cytarabine; mitoxantrone hydrochloride; laboratory biomarker analysis

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using Azacitidine; Pre-DLI Salvage Chemotherapy; Donor Leukocyte Infusion (DLI)

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation.
Azacitidine; Pre-DLI Salvage Chemotherapy; Donor Leukocyte Infusion (DLI)

Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, or Myelod Clinical Trial using brentuximab vedotin

Washington University School of Medicine - Recruiting 18 years to 65 years.
- A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation.
brentuximab vedotin

Leukemia, Myeloid, Acute Clinical Trial using G-CSF; Plerixafor; Mitoxantrone; Etoposide; Cytarabine

Washington University School of Medicine - Recruiting 18 years to 70 years.
- Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia.
G-CSF; Plerixafor; Mitoxantrone; Etoposide; Cytarabine

Acute Myeloid Leukemia Clinical Trial using Sorafenib

Massachusetts General Hospital - Recruiting 18 years to 75 years.
- Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation.
Sorafenib

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MD Clinical Trial using Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Allogeneic Transplant for Hematological Malignancy.
Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using midostaurin

Novartis - Recruiting 3 Months to 18 years.
- A Phase I/II, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients With Relapsed or Refractory Leukemia.
midostaurin

Acute Myeloid Leukemia Clinical Trial using sorafenib, vorinostat and bortezomib

Indiana University - Recruiting 18 years or older.
- Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype.
sorafenib, vorinostat and bortezomib

Acute Myeloid Leukemia Clinical Trial using midostaurin (PKC412)

Technische Universit„t Dresden - Recruiting 18 years to 65 years.
- A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML.
midostaurin (PKC412)

Acute Myeloid Leukemia Clinical Trial using idarubicin; microtransplantation

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences - Recruiting 7 years to 60 years.
- HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia.
idarubicin; microtransplantation

Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Myeloprolife Clinical Trial using ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Hospital Israelita Albert Einstein - Recruiting 18 years to 60 years.
- Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis.
ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Leukemia Clinical Trial using flow cytometry; immunologic technique; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 15 years or older.
- A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project.
flow cytometry; immunologic technique; laboratory biomarker analysis

Acute Myeloid Leukemia, or Acute Lymphocytic Leukemia Clinical Trial using DFP-10917

Delta-Fly Pharma, Inc. - Recruiting 18 years or older.
- A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia.
DFP-10917

Leukemia, or Myelodysplastic Syndromes Clinical Trial using clofarabine; cytarabine; idarubicin

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 60 years.
- Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial).
clofarabine; cytarabine; idarubicin

Acute Myeloid Leukemia Clinical Trial using Exercise; Control

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase II Exercise RCT for AML Patients Undergoing Induction Chemotherapy.
Exercise; Control

Acute Myeloid Leukemia Clinical Trial using plerixafor; decitabine

Weill Medical College of Cornell University - Recruiting 60 years or older.
- Induction Therapy With Decitabine and Plerixafor Priming for Patients ò 60 Years With Acute Myeloid Leukemia.
plerixafor; decitabine

Acute Myeloid Leukemia Clinical Trial using Revlimid

University Health Network, Toronto - Recruiting 18 years or older.
- A Randomized Phase II Study of Lenalidomide Maintenance Therapy in AML Patients Aged > 60 Years in CR1 or Higher and < 60 Years in CR2 or Higher.
Revlimid

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using ATG FRESENIUS (Anti-Lymphocyte-Globulin)

Universit„tsklinikum Hamburg-Eppendorf - Recruiting 18 years to 65 years.
- Prophylaxis of Chronic Graft-Versus-Host Disease (cGvHD) With or Without Anti-T-Lymphocyte-Globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-Identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-Study.
ATG FRESENIUS (Anti-Lymphocyte-Globulin)

Acute Myeloid Leukemia Clinical Trial using FLAG+IDA

Cooperative Study Group A for Hematology - Recruiting 15 years to 60 years.
- Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia.
FLAG+IDA

AML Clinical Trial using Glivec; Mitoxantrone; Topotecan; AraC

Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older.
- Open-Label Multicenter Trial of Glivecr (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML).
Glivec; Mitoxantrone; Topotecan; AraC

Acute Myeloid Leukemia, or Elderly Clinical Trial using Azacitidine

Kansas City Veteran Affairs Medical Center - Recruiting 60 years or older.
- A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study.
Azacitidine

Leukemia, Myeloid, Acute Clinical Trial using RFUSIN2-AML1; Donor leukocyte infusion (DLI); RFUSIN2-AML1 and donor leukocyte infusion

King's College Hospital NHS Trust - Recruiting 18 years or older.
- A Phase I Study of Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) Expressing B7.1 (CD80) and IL-2 for the Potential Enhancement of Graft Versus Leukaemia(GvL) Effect in Poor Prognosis AML.
RFUSIN2-AML1; Donor leukocyte infusion (DLI); RFUSIN2-AML1 and donor leukocyte infusion